Singapore’s Mirxes Gains Hang Seng Composite Index Inclusion, Expands Investor Base

Singapore-based biotech start-up Mirxes is slated for inclusion in the Hang Seng Composite Index (HSCI) on September 8, merely three months after its Hong Kong Stock Exchange listing. The move is expected to enhance the company’s visibility in the market and increase trading activity, marking a notable achievement for a Singapore biotech firm on the international stage.

The Hang Seng Composite Index, which covers roughly 95% of the total market value of companies listed on Hong Kong’s mainboard, features major Chinese firms such as Alibaba, Tencent, and BYD. Inclusion in the index positions Mirxes alongside these established players and underscores the growing recognition of biotech companies in the region.

Unlike the blue-chip Hang Seng Index, which tracks only the largest and most actively traded 85 stocks in Hong Kong, the Hang Seng Composite Index covers a broader spectrum of the market. Mirxes’ inclusion in the HSCI is expected to enhance its appeal to a wider range of investors, including institutional funds and exchange-traded funds that track the index.

The listing also allows Mirxes’ shares to be included in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, giving investors in mainland China the opportunity to trade the stock. The company stated that this broadens its investor base significantly, providing access to a vital source of capital to fuel long-term growth and innovation.

Mirxes joins the HSCI just over three months after its Hong Kong debut on May 15. Shares had opened at HK$23.30 and closed the first day of trading at HK$30, representing a gain of 28.8%, reflecting strong early market interest.

After the recent index review, Mirxes will join 16 other biotech companies in the Hang Seng Composite Index, out of the 76 biotech firms listed on HKEX through the Chapter 18A route since 2018. The company highlighted that its inclusion reflects its strong market standing and performance since going public.

The change will take effect on September 8, following market close on September 5. Inclusion in the index is expected to improve liquidity and visibility, boosting Mirxes’ profile among investors and supporting its strategic positioning in Hong Kong and the wider Asian capital markets.

By expanding its investor base and enhancing access to institutional and mainland Chinese investors, Mirxes is well-positioned to strengthen its capital foundation and support the growth of its molecular cancer early detection business.

Image credits: Mirxes